Drugs / 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

Follow last change Jun 2022 re-read 2 minutes ago

11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

Developed for: human papilloma virus infection · cervical carcinoma · human papillomavirus-related squamous cell carcinoma
Investigated by: Beijing Kantorico Statistical Technology Co., Ltd. · Chengdu Institute of Biological Products Co.,Ltd. · Guangxi Center for Disease Control and Prevention · National Vaccine and Serum Institute, China · Simoon Record Pharma Information Consulting Co., Ltd. · Centers for Disease Control and Prevention, China
+2 more
· Hunan Provincial Center for Disease Control and Prevention · Sichuan Center for Disease Control and Prevention

202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 11 trial
Phase 1	NCT04083196	Sep 2019 → Oct 2021	cervical carcinoma, human papilloma virus infection	National Vaccine and Serum Institute, China	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT04436133	Jun 2020 → Mar 2022	cervical carcinoma, human papilloma virus infection	National Vaccine and Serum Institute, China	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT05262010	Jun 2022 → Jun 2028 expected	human papilloma virus infection, human papillomavirus-related squamous cell carcinoma	National Vaccine and Serum Institute, China	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04083196 ↗ 2 NCT04436133 ↗ NCT05262010 ↗
Modality	Vaccine	“11-valent Recombinant Human Papillomavirus Vaccine” NCT04083196 ↗
Route	Intramuscular	“intramuscular injection of the upper arm deltoid muscle” NCT04083196 ↗